Close this search box.

Superficial Radiotherapy: The Non-Invasive Skin Cancer Treatment Option for You

March 24, 2017

If you have been diagnosed with non-melanoma skin cancer such as basal cell or squamous cell carcinoma, there are multiple options for treatment.

Invasive Options

With Mohs surgery, surgeons slice thin layers of skin from your body, test the cells for cancer, and continue until the tests come back negative. Mohs surgery offers high success rates but comes with baggage. Mohs surgery can be extremely invasive, require lengthy recovery times, and can even cause scarring so severe that plastic surgery is the only option to recover.

Excision, another invasive surgery option, has lower success rates than Mohs surgery. Rather than running the pathology during the surgery, surgeons cut one larger piece of skin, with room for insurance, and results are unclear for a few days to a week after surgery is complete.

Electrodesiccation and curettage is a process involving, like the previous options, the scraping of cancer cells of the dermis. After the scraping, an electrosurgical device is used to denature the next layer. Then the scraping resumes. Success depends entirely on the aggressiveness of the surgeon and the width of the surgical margin.

The Non-Invasive Skin Cancer Treatment Option for You

Rather than going into surgery, choose Superficial Radiotherapy via the SRT-100™ or SRT-100 Vision™ to treat your non-melanoma skin cancer. This treatment option boasts high rates of success (95+%), no cutting, no scraping, no pain, and no downtime. Instead of going under the knife, the SRT-100™ delivers precise, painless doses of Superficial Radiotherapy to target and eliminate non-melanoma skin cancer cells.

This option is a wonderful choice for anyone with basal or squamous cell carcinomas on the hands, face, ears, and neck, or for those who are unable to go under anesthesia for surgery. If you’re interested in learning more about non-invasive skin cancer treatment options like the SRT-100™, contact Sensus Healthcare today.